Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target at $94.57

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $94.57.

A number of research analysts have recently issued reports on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald started coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price for the company. Finally, Oppenheimer reissued an “outperform” rating and issued a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LMAT. Townsquare Capital LLC lifted its holdings in shares of LeMaitre Vascular by 38.0% in the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock valued at $4,454,000 after buying an additional 13,210 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in LeMaitre Vascular by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock valued at $17,789,000 after acquiring an additional 11,395 shares during the last quarter. Barclays PLC boosted its position in shares of LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after purchasing an additional 29,180 shares in the last quarter. Nicholas Investment Partners LP acquired a new position in shares of LeMaitre Vascular in the 2nd quarter worth approximately $3,900,000. Finally, Creative Planning raised its holdings in shares of LeMaitre Vascular by 20.7% in the 3rd quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock worth $334,000 after purchasing an additional 617 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $92.84 on Monday. The stock has a 50-day simple moving average of $97.93 and a 200 day simple moving average of $90.42. LeMaitre Vascular has a one year low of $52.88 and a one year high of $109.58. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of 50.73, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same period in the previous year, the business earned $0.33 EPS. The business’s quarterly revenue was up 15.6% on a year-over-year basis. On average, equities research analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were paid a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.69%. LeMaitre Vascular’s payout ratio is 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.